🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is there a Clinical Utility for Tissue- and Blood-derived Genomic Biomarkers in metastatic hormone-sensitive #ProstateCancer? Check out our systematic review on genomic alterations in mHSPC reported in European Urology Oncology: authors.elsevier.com/a/1e5cE9Cfv-qB… [1/7]

Congratulations to Bruce G. Haffty, MD, 2022 RSNA President! Dr. Haffty plans to focus on expanding RSNA’s profile in the broader medical community and to promote the value of radiology to patients & partners in health care delivery. bit.ly/3D9GBDa #RSNA21 Bruce Haffty

-BRPC/LAPC, n=132 -SBRT ☢️, 33 Gy/5 fx -Dose to vertebral bodies (VB) and spleen ➡️ G2+ lymphopenia and ⬇️ALC -Thresholds: VB V15≥5.84%, VB V2.5≥48.4%, spleen V10≥4.17% -prior data shows lymphopenia ➡️ ❌ outcomes - ➡️VB and spleen as OARs? ro-journal.biomedcentral.com/articles/10.11…

Definitions of disease burden across the spectrum of #mCSPC: Comparison by disease outcomes & genomics. #BeyondTheAbstract on UroToday > bit.ly/3u9yG8a Prostate Cancer and Prostatic Diseases Matthew P Deek Amar Kishan AttardLab Anis Hamid Ashley Ross MD PhD Piet Ost Emmanuel Antonarakis Felix Feng

Definitions of disease burden across the spectrum of #mCSPC: Comparison by disease outcomes & genomics. #BeyondTheAbstract on UroToday > bit.ly/3u9yG8a Prostate Cancer and Prostatic Diseases Matthew P Deek Amar Kishan AttardLab Anis Hamid Ashley Ross MD PhD Piet Ost Emmanuel Antonarakis Felix Feng

Counting mets is currently used for deciding to debulk, to give chemo (NCCN&ASCO only), and triplet (PEACE1). Will the detection of genomic mutations (tp53, DNA-DSB, WNT) replace it? Nick James also on @Prof-Nick-James.bsky.social Piet Ost Alejandro (Ale) Berlin Emmanuel Antonarakis AttardLab europeanurology.com/article/S0302-…

Congratulations to our PGY-4 resident Jongmyung Kim, MD PhD Rutgers Radiation Oncology Residency Program Rutgers Cancer Institute for his study on genetic alterations in pancreatic cancer being accepted for presenting at Radiation Research Society annual meeting this year. This study was mentored by our faculty Matthew P Deek and Salma Jabbour

Enjoyed working with Piet Ost Kim Van der Eecken and Phu Tran on this. Hopefully we can continue to better understand the biology of oligometastasis to personalize treatment. Rutgers Cancer Institute

🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer 🎯 Largest benefit for patients harboring a high-risk mutation #PCSM Matthew P Deek Piet Ost fal.cn/3s1ch

SBRT for oligometastasis: GUst do it? Check out our oncology scan in IJROBP - The Red Journal with oligomet experts Alejandro (Ale) Berlin @drdavidpalma Matthew P Deek C. Jillian Tsai, MD, PhD Shankar Siva Piet Ost authors.elsevier.com/a/1fvZq1Hx52CH… . Thank you Alejandro (Ale) Berlin Sue Yom IJROBP - The Red Journal for the opportunity!

Please come and join our faculty Matthew P Deek presenting his study on oligometasis #ASTRO2022 ASTRO Rutgers Radiation Oncology Residency Program Rutgers Cancer Institute Rutgers RWJMedSchool Rutgers New Jersey Medical School

Multi-institutional analysis of metastasis directed therapy with or without ADT in oligometastatic castration-sensitive #ProstateCancer. Presented by Matthew P Deek RWJBarnabas. #AUA23 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3oXLQ7B Amer. Urol. Assn.

Strong #radonc representation at the #PCFAcademy 💪🏽& thrilled to put together an all ⭐️ RT session. Excellent discussions & ideas to improve treatments & outcomes for our PCa pts. “RT is a powerful anti-cancer agent.” Let’s further harness it for the future: CHARGE!

Congratulations to Rutgers Radiation Oncology Residency Program faculty, Dr. Deek Matthew P Deek and chief resident, Dr. Kim Jongmyung Kim, MD PhD for being recognized by ASTRO for their contributions to the advancement of our field. Rutgers Cancer Institute Rutgers RWJMedSchool Rutgers New Jersey Medical School RWJBarnabas

Phuoc Tran with the Mentorship Award!! Well deserved—such a fantastic champion of others in the field 🙌🏼👏🏻 Kekoa Taparra, MD, PhD, MPH Sophia Kamran, MD Rana McKay, MD, FASCO NRG Oncology ASTRO #ASTRO23

Erin Gillespie, MD MPH Rupesh Kotecha Simon Powell C. Jillian Tsai, MD, PhD @JYangMDPhD Excellent editorial Matthew P Deek Dr. Tran & Salma Jabbour Eval for Met Directed Tx: •Oligo Mets •Oligo Prog Dz •Proph High Risk Dz •Symptomatic Dz   doi.org/10.1200/jco.23…

This multi-institutional study highlights the benefits of combining MDT with ADT for oligometastatic castration-sensitive #ProstateCancer. Findings suggest improved progression-free survival with combined treatment vs MDT alone. #AuthorCommentary from Matthew P Deek, Philip Sutera,

This multi-institutional study highlights the benefits of combining MDT with ADT for oligometastatic castration-sensitive #ProstateCancer. Findings suggest improved progression-free survival with combined treatment vs MDT alone. #AuthorCommentary from Matthew P Deek, Philip Sutera,

AI in Radiation Therapy: Steve Jiang, Matthew P Deek, Danielle S. Bitterman, Philip A. Sutera, and Ruijiang Li addressed this topic in a plenary session at the AACR Conference on Translating Targeted Therapies in Combination with Radiotherapy. #AACRradiation25 Danielle Bitterman, MD

Phase 2 Randomized High-risK metachroNous oligometastatIc #ProstateCancer with hiGh-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/abiraterone Acetate + Prednisone - The #KNIGHTS trial. The phase 2 KNIGHTS trial is testing MDT + niraparib/abiraterone in